India Hemoglobinopathies Market Size & Outlook, 2022-2030
India hemoglobinopathies market, 2018-2030 (US$M)
Related Markets
India hemoglobinopathies market highlights
- The India hemoglobinopathies market generated a revenue of USD 262.5 million in 2022 and is expected to reach USD 743.4 million by 2030.
- The India market is expected to grow at a CAGR of 13.9% from 2023 to 2030.
- In terms of segment, sickle cell disease was the largest revenue generating disease type in 2022.
- Sickle cell disease is the most lucrative disease type segment registering the fastest growth during the forecast period.
Hemoglobinopathies market data book summary
| Market revenue in 2022 | USD 262.5 million |
| Market revenue in 2030 | USD 743.4 million |
| Growth rate | 13.9% (CAGR from 2022 to 2030) |
| Largest segment | Sickle cell disease |
| Fastest growing segment | Sickle cell disease |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Thalassemia, Sickle cell disease, Other Hb Variants |
| Key market players worldwide | Sangamo Therapeutics Inc, Global Blood Therapeutics, Bluebird bio Inc, Emmaus Life Sciences Inc, Pfizer Inc, Novartis AG ADR, Prolong Pharmaceuticals, Bioverativ, Gamida Cell, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, India accounted for 1.7% of the global hemoglobinopathies market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China hemoglobinopathies market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,635.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hemoglobinopathies Market Scope
Hemoglobinopathies Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
India hemoglobinopathies market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemoglobinopathies market will help companies and investors design strategic landscapes.
Sickle cell disease was the largest segment with a revenue share of 59.28% in 2022. Horizon Databook has segmented the India hemoglobinopathies market based on thalassemia, sickle cell disease, other hb variants covering the revenue growth of each sub-segment from 2018 to 2030.
Various initiatives aimed at providing high-quality and affordable care to patients with hemoglobinopathies are anticipated to drive the market growth in India. For instance, in August 2018, the Ministry of Health and Family Welfare released the new draft policy for hemoglobinopathies.
The policy focuses on strengthening treatment centers in all districts in the country with an aim to improve patient access to treatment and services for managing these disorders. Setting up of bone marrow transplant facilities in tertiary care institutions, launch of carrier screening programs for SCD, thalassemia, HbE, HbS, etc., and improving facilities for blood components separation & blood storage are some of the measures included in the draft policy.
Furthermore, as per a report by Springer Nature Limited in 2018, Indian population holds the highest frequency of βS allele. The carrier frequency varies between 5% and 12%, depending upon the population. This is expected to create growth opportunity for market players.
Reasons to subscribe to India hemoglobinopathies market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of India hemoglobinopathies market databook
-
Our clientele includes a mix of hemoglobinopathies market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India hemoglobinopathies market , including forecasts for subscribers. This country databook contains high-level insights into India hemoglobinopathies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
India hemoglobinopathies market size, by disease type, 2018-2030 (US$M)
India Hemoglobinopathies Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
